• Captopril’s Dual Mechanisms: Bridging ACE Inhibition and GI

  2026-05-05

  This thought-leadership article explores the mechanistic intricacies and translational opportunities of Captopril, a gold-standard ACE inhibitor. By integrating cardiovascular and gastrointestinal research, it provides actionable guidance for scientists seeking to leverage Captopril’s dual role in hypertension and oncology, while bridging into bradykinin-mediated modulation of peristalsis. The article highlights evidence-based protocols, competitive insights, and a forward-looking perspective on cross-domain research.

• Preclinical Characterization of Anlotinib: Selective VEGFR2

  2026-05-04

  This article examines the preclinical study of anlotinib hydrochloride, a highly selective multi-target tyrosine kinase inhibitor with potent anti-angiogenic activity. The research demonstrates anlotinib’s superior efficacy in inhibiting VEGFR2-mediated angiogenesis and tumor growth, providing a strong foundation for its application in cancer research.

• Phosphatase Inhibitor Cocktail 1: Preserving Cardiac Signali

  2026-05-04

  Explore how Phosphatase Inhibitor Cocktail 1 ensures robust protein phosphorylation preservation in cardiovascular research. This article uniquely connects single-cell signaling insights with advanced assay strategies for heart failure models.

• Bradykinin B2 Receptors Inhibit Ileal Peristalsis: Mechanist

  2026-05-03

  This study delivers the first direct evidence that bradykinin modulates gastrointestinal motility by inhibiting the peristaltic reflex via B2 receptor activation in the guinea pig ileum. The findings clarify receptor-specific control of gut peristalsis and offer a mechanistic foundation relevant to ACE inhibition research and bradykinin pathway modulation.

• Catalpol’s Protective Roles in Cardio-Cerebrovascular Diseas

  2026-05-02

  This review comprehensively examines catalpol, an iridoid glucoside from Rehmannia glutinosa, highlighting its multi-pathway mechanisms in protecting against cardio-cerebrovascular diseases (CVDs). The article situates catalpol’s molecular actions within the context of contemporary hypertension and cardiovascular research, drawing methodologic parallels to established ACE inhibitor workflows.

• Angiotensin III: Strategic Insights for Translational Resear

  2026-05-01

  This thought-leadership article explores Angiotensin III (human, mouse) as a next-generation RAAS peptide, blending mechanistic detail with actionable guidance for cardiovascular, neuroendocrine, and emerging viral pathogenesis research. We contextualize recent mechanistic breakthroughs, validate experimental protocols, and strategically position Angiotensin III for translational innovation—bridging preclinical discovery and clinical opportunity.

• Controlled Self-Renewal and Differentiation in Human Intesti

  2026-05-01

  This study establishes a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation without the need for artificial niche gradients. By leveraging small molecule pathway modulators, the system enhances both proliferative capacity and cellular diversity, opening new possibilities for high-throughput tissue modeling and disease research.

• Calpeptin: Calpain Inhibitor Workflows for Fibrosis Research

  2026-04-30

  Calpeptin is a nanomolar-potency calpain inhibitor that empowers advanced pulmonary fibrosis and inflammation research. This article details stepwise protocols, troubleshooting, and translational strategies—bridging bench findings to robust, reproducible results.

• Angiotensin 1/2 (1-6): Precision Tool for RAS Research & Ass

  2026-04-30

  Angiotensin 1/2 (1-6) provides unique mechanistic leverage for dissecting renin-angiotensin system (RAS) signaling in cardiovascular and renal models. This article distills evidence-backed workflow strategies, troubleshooting insights, and translational guidance for maximizing data quality and experimental impact with this high-purity Asp-Arg-Val-Tyr-Ile-His hexapeptide.

• Optimized Differentiation of Platelets from hiPSCs Using Sma

  2026-04-29

  This study presents a systematically optimized protocol for producing functional platelets from human induced pluripotent stem cells (hiPSCs). By increasing embryoid body input, refining media, and substituting select cytokines with small molecules, the method improves yield, accelerates differentiation, and reduces costs, enabling more scalable cell therapy and gene editing applications.

• Angiotensin 1/2 (2-7): Experimental Leverage in RAS Research

  2026-04-29

  Angiotensin 1/2 (2-7) empowers cardiovascular and translational researchers with a high-purity, workflow-ready vasoconstrictor peptide fragment. Its unique sequence, robust solubility, and validated role in both blood pressure regulation and emerging viral pathogenesis models set it apart for advanced assay design and troubleshooting.

• Nuclear cGAS-TRIM41 Axis Restricts LINE-1 via Chk2 Phosphory

  2026-04-28

  This study uncovers a nuclear role for cGAS in repressing LINE-1 (L1) retrotransposition by promoting TRIM41-mediated ORF2p ubiquitination and degradation, a process dependent on Chk2-mediated cGAS phosphorylation. These findings refine our understanding of genome stability mechanisms and highlight the DNA damage response's impact on L1 control, with practical implications for aging and cancer research.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-04-28

  This study systematically characterizes the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice with metabolic dysfunction-associated steatohepatitis (MASH). The findings highlight how disease status and dosing frequency modulate systemic exposure and liver accumulation of key alkaloids, informing rational dosage strategies for MASLD/MASH therapy.

• Cleavage-Resistant TREM2 Enhances Macrophage Efferocytosis i

  2026-04-27

  Dong et al. engineered a synthetic, cleavage-resistant TREM2 (CRT) that resists ADAM17-mediated proteolysis, restoring TREM2 signaling in inflammatory settings. Their approach selectively delivers CRT-encoding mRNA to macrophages, boosting efferocytosis and reducing inflammation in models of steatohepatitis and atherosclerosis.

• Technical Guide: Hoechst 33342/PI Double Staining Kit (K2237

  2026-04-27

  The Hoechst 33342/PI Double Staining Kit enables researchers to distinguish apoptotic, necrotic, and viable cells in fluorescence assays by differentially labeling nuclear chromatin and membrane integrity. This kit is intended for microscopy-based cell death analysis in basic research and is not suitable for diagnostic or clinical use.

15292 records 1/1020 page Next 12345 下5页 Last page